Victoria Stepanyants
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Stepanyants has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Anne Brooks
Parkinson's Foundation Miami Florida USA
1 shared publicationAnthony Leung
Department of Infectious Diseases, Cleveland Clinic Foundation
1 shared publication- Benjamin L. Walter
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195, USA
1 shared publication - Betty Ky Hamilton
Cleveland Clinic
1 shared publication - Brent S. Sokola
University of Kentucky, Lexington, KY, USA
1 shared publication - Camila Callegari Piccinin
Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, OH, USA
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 1068-1079
Effects of an Inpatient Program on Medication Errors in Hospitalized People with Parkinson's Disease
Objective: Hospitalized people with Parkinson's disease (PwP) face increased risks of medication errors and discharge to non‐home settings, both of which are associated with adverse outcomes. This study assessed differences in medication error rates and discharge outcomes before and after implementation of a dedicated inpatient program for hospitalized PwP. Methods: During 2023, a Parkinson's disease (PD) inpatient program was implemented and refined combining: (1) an electronic health record (EHR) census for identification of hospitalized PwP; (2) inpatient monitoring and alignment of inpatient and outpatient regimens by movement‐disorders‐trained advanced practitioners; (3) customized EHR alerts and levodopa orders; (4) pharmacist support, and (5) staff education. Medication error rates and clinical outcomes were compared between January and June 2024 (post‐implementation phase) and a pre‐implementation retrospective cohort from 2018. Results: From January to June 2024, 366 post‐implementation admissions were monitored. Among those receiving contraindicated medications, the median number of doses decreased from 2 (interquartile range [IQR] = 1–6) during pre‐implementation to 1 (IQR: 1–2) post‐implementation ( p = 0.015). Days with a levodopa dose deviation decreased from 43.1% to 38.3%, p < 0.0001, improper levodopa formulation substitutions from 18.6% to 5%, p < 0.0001, timing deviations from 72.2% to 51.8%, p < 0.00001, missed doses from 21.5% to 16.8%, p = 0.013, and discharged to non‐home settings from 44.8% to 38.3%, p = 0.038. Interpretation: Following implementation of a multidisciplinary and proactive inpatient program, reductions in medication errors and improved discharge outcomes were observed among PwP. ANN NEUROL 2026;100:1068–1079
- 31 August 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 1068-1079
Open AccessEffects of an Inpatient Program on Medication Errors in Hospitalized People with Parkinson's Disease
Objective: Hospitalized people with Parkinson's disease (PwP) face increased risks of medication errors and discharge to non‐home settings, both of which are associated with adverse outcomes. This study assessed differences in medication error rates and discharge outcomes before and after implementation of a dedicated inpatient program for hospitalized PwP. Methods: During 2023, a Parkinson's disease (PD) inpatient program was implemented and refined combining: (1) an electronic health record (EHR) census for identification of hospitalized PwP; (2) inpatient monitoring and alignment of inpatient and outpatient regimens by movement‐disorders‐trained advanced practitioners; (3) customized EHR alerts and levodopa orders; (4) pharmacist support, and (5) staff education. Medication error rates and clinical outcomes were compared between January and June 2024 (post‐implementation phase) and a pre‐implementation retrospective cohort from 2018. Results: From January to June 2024, 366 post‐implementation admissions were monitored. Among those receiving contraindicated medications, the median number of doses decreased from 2 (interquartile range [IQR] = 1–6) during pre‐implementation to 1 (IQR: 1–2) post‐implementation ( p = 0.015). Days with a levodopa dose deviation decreased from 43.1% to 38.3%, p < 0.0001, improper levodopa formulation substitutions from 18.6% to 5%, p < 0.0001, timing deviations from 72.2% to 51.8%, p < 0.00001, missed doses from 21.5% to 16.8%, p = 0.013, and discharged to non‐home settings from 44.8% to 38.3%, p = 0.038. Interpretation: Following implementation of a multidisciplinary and proactive inpatient program, reductions in medication errors and improved discharge outcomes were observed among PwP. ANN NEUROL 2026;100:1068–1079
- Open Access
- 25 June 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (8) , e0025626
Risk assessment and mitigation of hepatitis C virus RNA carryover contamination in a reflex testing algorithm
Laboratory-based diagnosis of active hepatitis C virus (HCV) infection currently requires a positive antibody test and a confirmatory RNA test. Many institutions in the United States continue to require two separate sample collections, partially due to concerns for carryover contamination. Reflexive RNA testing of antibody-positive samples reduces loss to follow-up, improves linkage to care, and is a recommended operational strategy by the Centers for Disease Control and Prevention. This study describes false positivity rates of reflexive RNA testing in a reference laboratory before and after introduction of a risk mitigation strategy that requires medical director review for reflexed HCV viral loads < 1,000 IU/mL (defined as low-positive). Initial HCV antibody testing was performed at one of five chemistry laboratories; reflex HCV RNA testing was performed using the cobas HCV assay on cobas 8800 (Roche) at a central reference laboratory. A total of 4,079 consecutive positive RNA results were included pre-intervention, and 4,433 were included post-intervention. All low-positive results ( N = 157) were retrospectively adjudicated as true-positive ( N = 66), false-positive ( N = 38), or unknown ( N = 53), based on clinical history and redraw results. The pre-intervention false-positive rate was 0.44%, which was significantly reduced to 0.14% post-intervention, P = 0.008. Median viral load for those clinically adjudicated as true-positive was significantly higher at 97 IU/mL (IQR: 24, 330 IU/mL) compared to 17 IU/mL (IQR: 14, 58 IU/mL) classified as false-positive or 16 IU/mL (IQR: 14, 62 IU/mL) classified as unknown. This study supports wider implementation of reflexive RNA testing for antibody-positive samples and provides a blueprint for a risk mitigation strategy. IMPORTANCE: Most patients infected with hepatitis C virus are unable to spontaneously clear the virus and develop chronic infection. Chronic hepatitis C virus (HCV) infection can lead to life-threatening complications including liver cirrhosis, liver failure, and liver cancer. Therefore, accurate diagnosis of hepatitis C infection and linkage to treatment is paramount. To increase linkage to care, current Centers for Disease Control and Prevention (CDC) guidelines recommend single-visit sample collection to test for antibodies and, if antibody positive, viral RNA. However, almost half of the laboratories do not use reflexive testing strategies, in part due to concerns for carryover contamination. Our study describes a low risk of false-positive RNA results and suggests a risk mitigation intervention to further minimize false positives. Our work reaffirms CDC guidelines and provides real-world data to encourage other facilities to follow a reflex testing algorithm to increase linkage to care.
- 25 June 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (8) , e0025626
Open AccessRisk assessment and mitigation of hepatitis C virus RNA carryover contamination in a reflex testing algorithm
Laboratory-based diagnosis of active hepatitis C virus (HCV) infection currently requires a positive antibody test and a confirmatory RNA test. Many institutions in the United States continue to require two separate sample collections, partially due to concerns for carryover contamination. Reflexive RNA testing of antibody-positive samples reduces loss to follow-up, improves linkage to care, and is a recommended operational strategy by the Centers for Disease Control and Prevention. This study describes false positivity rates of reflexive RNA testing in a reference laboratory before and after introduction of a risk mitigation strategy that requires medical director review for reflexed HCV viral loads < 1,000 IU/mL (defined as low-positive). Initial HCV antibody testing was performed at one of five chemistry laboratories; reflex HCV RNA testing was performed using the cobas HCV assay on cobas 8800 (Roche) at a central reference laboratory. A total of 4,079 consecutive positive RNA results were included pre-intervention, and 4,433 were included post-intervention. All low-positive results ( N = 157) were retrospectively adjudicated as true-positive ( N = 66), false-positive ( N = 38), or unknown ( N = 53), based on clinical history and redraw results. The pre-intervention false-positive rate was 0.44%, which was significantly reduced to 0.14% post-intervention, P = 0.008. Median viral load for those clinically adjudicated as true-positive was significantly higher at 97 IU/mL (IQR: 24, 330 IU/mL) compared to 17 IU/mL (IQR: 14, 58 IU/mL) classified as false-positive or 16 IU/mL (IQR: 14, 62 IU/mL) classified as unknown. This study supports wider implementation of reflexive RNA testing for antibody-positive samples and provides a blueprint for a risk mitigation strategy. IMPORTANCE: Most patients infected with hepatitis C virus are unable to spontaneously clear the virus and develop chronic infection. Chronic hepatitis C virus (HCV) infection can lead to life-threatening complications including liver cirrhosis, liver failure, and liver cancer. Therefore, accurate diagnosis of hepatitis C infection and linkage to treatment is paramount. To increase linkage to care, current Centers for Disease Control and Prevention (CDC) guidelines recommend single-visit sample collection to test for antibodies and, if antibody positive, viral RNA. However, almost half of the laboratories do not use reflexive testing strategies, in part due to concerns for carryover contamination. Our study describes a low risk of false-positive RNA results and suggests a risk mitigation intervention to further minimize false positives. Our work reaffirms CDC guidelines and provides real-world data to encourage other facilities to follow a reflex testing algorithm to increase linkage to care.
- 31 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1410-1412
Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil
- 31 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1410-1412
Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil